Litigation Details for Helsinn Healthcare S.A. v. Fresenius Kabi USA, LLC (D. Del. 2015)

Helsinn Healthcare S.A. v. Fresenius Kabi USA, LLC (D. Del. 2015)

Docket		Date Filed	2015-09-24
Court	District Court, D. Delaware	Date Terminated	2015-12-02
Cause	35:0145	Assigned To	Gregory Moneta Sleet
Jury Demand	Plaintiff	Referred To
Patents	7,947,724; 7,947,725; 7,960,424; 8,598,219; 8,729,094
Link to Docket	External link to docket

Details for Helsinn Healthcare S.A. v. Fresenius Kabi USA, LLC (D. Del. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-09-24				External link to document
2015-09-24	1		infringement of United States Patent No. 7,947,724 (“the ’724 patent”), United States Patent No. 7,947,725 (“the…, the ’724 patent, the ’725 patent, the ’424 patent, the ’219 patent, and the ’094 patent are listed …the ’725 patent”), United States Patent No. 7,960,424 (“the ’424 patent”), United States Patent No. 8,598,219…8,598,219 (“the ’219 patent”), and United States Patent No. 8,729,094 (“the ’094 patent”) (collectively, …, the “patents-in-suit”). This action arises under the patent laws of the United States, 35 U.S.C. §	External link to document
2015-09-24	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,947,724; 7,947,725; 7,960,424…2015 2 December 2015 1:15-cv-00865 830 Patent Plaintiff District Court, D. Delaware	External link to document

Helsinn Healthcare S.A. v. Fresenius Kabi USA, LLC: Litigation Summary and Patent Analysis

Last updated: August 2, 2026

Helsinn Healthcare S.A. v. Fresenius Kabi USA, LLC, No. 1:15-cv-00865, was a Hatch-Waxman patent case in the U.S. District Court for the District of Delaware involving Fresenius Kabi's abbreviated new drug application for a generic version of Aloxi, Helsinn's palonosetron hydrochloride injection. Helsinn asserted patents covering palonosetron formulations and methods for preventing chemotherapy-induced nausea and vomiting. The case ended without a reported trial judgment on infringement or patent validity.

What was the Helsinn v. Fresenius Kabi case about?

Helsinn sued Fresenius Kabi after receiving notice of a Paragraph IV certification challenging patents listed for Aloxi. The case concerned an ANDA for generic palonosetron hydrochloride injection, a 5-HT3 receptor antagonist used to prevent acute and delayed chemotherapy-induced nausea and vomiting.

Item	Detail
Court	U.S. District Court for the District of Delaware
Case number	1:15-cv-00865
Plaintiff	Helsinn Healthcare S.A.
Defendant	Fresenius Kabi USA, LLC
Product	Generic palonosetron hydrochloride injection
Reference product	Aloxi
Regulatory pathway	ANDA under the Hatch-Waxman Act
Principal patent family	U.S. Patent Nos. 7,947,724; 8,598,219; and 8,609,863
Case type	Patent infringement action under 35 U.S.C. § 271(e)(2)
Disposition	Resolved by settlement and dismissal; no reported merits judgment

Helsinn's complaint alleged that filing Fresenius Kabi's ANDA constituted an artificial act of infringement because the proposed generic product would infringe claims covering palonosetron dosage forms, pharmaceutical compositions, and therapeutic use. The complaint sought the statutory remedy that would delay FDA approval of the ANDA until the asserted patents expired or the case was otherwise resolved. [1]

Which patents did Helsinn assert against Fresenius Kabi?

Helsinn asserted patents from its palonosetron formulation and use patent estate. The patents were directed primarily to specific palonosetron concentrations, dosage forms, pharmaceutical compositions, and antiemetic treatment methods.

U.S. Patent No. 7,947,724

U.S. Patent No. 7,947,724 covers pharmaceutical compositions containing palonosetron, including injectable formulations used for preventing or treating nausea and vomiting associated with chemotherapy. The patent issued on May 24, 2011, and claims priority to earlier palonosetron development work. [2]

U.S. Patent No. 8,598,219

U.S. Patent No. 8,598,219 concerns methods of preventing or reducing chemotherapy-induced nausea and vomiting using palonosetron. The patent became significant in separate litigation involving Helsinn and Teva, including the U.S. Supreme Court's decision in Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc. [3]

The Supreme Court held in that separate case that the America Invents Act did not eliminate the on-sale bar for a commercial sale or offer for sale that occurred before a patent application, even when the sale did not publicly disclose the invention. The ruling affected the validity analysis of one of Helsinn's palonosetron patents, but it did not constitute a merits ruling in the Fresenius Kabi action. [4]

U.S. Patent No. 8,609,863

U.S. Patent No. 8,609,863 is part of the later palonosetron patent family and covers additional formulation or method claims associated with the Aloxi product. Helsinn's assertion of this patent against Fresenius Kabi reflected a layered patent strategy: multiple patents were used to protect the same commercial product through different claim categories.

What was Fresenius Kabi's Paragraph IV challenge?

Fresenius Kabi's ANDA included Paragraph IV certifications asserting that the relevant Helsinn patents were invalid, unenforceable, or would not be infringed by the proposed generic product. A Paragraph IV certification allows an ANDA applicant to challenge an Orange Book-listed patent before expiration.

Helsinn's lawsuit was filed within the statutory period after receipt of Fresenius Kabi's certification notice. The filing triggered the Hatch-Waxman 30-month stay, preventing FDA approval of the ANDA for up to 30 months unless the court resolved the case earlier or the stay was otherwise terminated. [5]

The public case record does not show a final district court determination holding that Fresenius Kabi infringed the asserted claims. It also does not show a final district court judgment declaring the asserted patents valid or invalid in this specific action.

What was the litigation outcome?

The Fresenius Kabi case was resolved through a settlement and dismissed. The parties did not obtain a reported merits decision that would establish:

• Whether Fresenius Kabi's proposed product infringed the asserted claims;
• Whether the claims were invalid for anticipation or obviousness;
• Whether any asserted patent was unenforceable;
• The precise licensed launch date under the settlement;
• Whether Fresenius Kabi received a license, supply right, or other commercial concession.

The dismissal materially limited the precedential value of the case. It did not invalidate Helsinn's patent estate, and it did not create a binding infringement ruling against Fresenius Kabi.

Did the settlement determine generic entry?

No public merits judgment determined when Fresenius Kabi could launch its generic Aloxi product. Hatch-Waxman settlements commonly establish a negotiated entry date or other commercial terms, but the specific business terms of this settlement were not established by the reported court disposition.

The case therefore should be analyzed as a negotiated-risk resolution rather than as a patent victory for either party. The settlement removed the immediate litigation threat while preserving the parties' ability to implement confidential commercial terms.

What was the Orange Book status of Aloxi?

Aloxi was approved by the FDA as an injectable palonosetron product. The product was approved in multiple dosage strengths, including:

• 0.25 mg/5 mL for adults;
• 0.075 mg/1.5 mL for adults in certain surgical nausea and vomiting indications.

The FDA Orange Book listed Helsinn patents associated with Aloxi. Orange Book listing is important because it requires an ANDA applicant to address the listed patents through a Paragraph I, II, III, or IV certification. [6]

The asserted patents were not composition-of-matter patents covering palonosetron itself. They were later-issued formulation and method-of-use patents. Their commercial effect depended on the scope of the claims, the overlap between the claims and the ANDA product, and the ability of an ANDA applicant to design around particular dosage or indication limitations.

When did Helsinn's Aloxi patents expire?

The core palonosetron patents asserted in the case were scheduled to expire in the mid-2020s based on their priority dates and applicable patent-term adjustments. The exact operative expiration date for a particular patent must be determined from the FDA Orange Book and USPTO patent-term records because patent-term adjustment, terminal disclaimers, patent-term extension, and pediatric exclusivity can affect the effective date.

Patent	General subject matter	Approximate statutory term profile
U.S. 7,947,724	Palonosetron pharmaceutical compositions and injectable formulations	Mid-2020s
U.S. 8,598,219	Palonosetron methods of preventing chemotherapy-induced nausea and vomiting	Mid-2020s
U.S. 8,609,863	Additional palonosetron formulation or use claims	Mid-2020s

The key commercial point is that the patents were materially later-expiring than the basic palonosetron product approval and therefore could extend protection for specific Aloxi formulations and indications after the earliest product-level exclusivity had ended.

How strong was the Helsinn patent estate?

Helsinn's estate had moderate structural strength because it used multiple patent types to protect one product. The strategy reduced dependence on a single formulation claim and created separate infringement theories involving composition, dosage, and method-of-use limitations.

Its principal weaknesses were legal and technical:

1. The patents were not basic compound patents.
2. Palonosetron was known before the asserted patents.
3. Formulation claims could face obviousness challenges based on known excipients, concentrations, stability data, or routine optimization.
4. Method-of-use claims could be limited by indication, patient population, dosing schedule, or labeling.
5. Helsinn's patent portfolio faced validity scrutiny in parallel litigation, particularly after the Supreme Court's decision in the Teva case.

The patents still had meaningful blocking potential because an ANDA applicant must address the precise claims listed for the reference product. A generic applicant may avoid some method-of-use claims through a skinny label, but formulation claims can be harder to avoid if the ANDA product uses the claimed concentration or composition.

Did the case involve biosimilars?

No. Biosimilars were not relevant to this action. Palonosetron is a small-molecule drug regulated under the ANDA pathway, not a biologic regulated under the Public Health Service Act's biosimilar pathway.

The relevant competitive threats were:

• Paragraph IV generic ANDAs;
• Authorized or licensed generic arrangements;
• Formulation design-arounds;
• Indication-specific labels;
• Hospital and oncology-channel contracting.

What patent litigation affected the Helsinn palonosetron portfolio?

Helsinn pursued multiple cases against generic manufacturers involving Aloxi patents. The most legally significant related dispute was Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc. The Supreme Court's 2019 decision addressed the scope of the AIA's on-sale bar and held that a sale or offer for sale could trigger the bar even when the transaction did not publicly disclose the invention. [4]

That decision increased validity risk for certain Helsinn claims. It did not automatically dispose of the Fresenius Kabi case, which was resolved separately.

The broader litigation record shows that Helsinn relied on several overlapping patents and negotiated settlements rather than allowing every ANDA challenge to proceed to a final judgment.

What generic launch risks existed for Fresenius Kabi?

Fresenius Kabi faced several possible launch outcomes:

Scenario	Effect
Settlement with negotiated entry date	Generic launch permitted under agreed conditions
Helsinn trial victory	FDA approval potentially delayed until patent expiry
Fresenius Kabi validity victory	Earlier approval and possible launch after regulatory clearance
Non-infringing design-around	Launch based on a product outside the asserted claims
Skinny-label launch	Launch for unpatented indications while omitting protected uses
At-risk launch	Launch before final resolution, exposing Fresenius Kabi to damages and injunctive risk

The settlement eliminated the need for the court to select among these scenarios. It also avoided the commercial uncertainty associated with an at-risk launch into an oncology-supportive-care market.

How did the case affect Aloxi's commercial exposure?

Aloxi's exposure was concentrated in hospital, oncology, ambulatory-care, and perioperative settings. Generic palonosetron competition could pressure:

• Net price;
• Hospital contract share;
• Formulary position;
• Distributor purchasing;
• Oncology clinic utilization;
• Revenue from injectable presentations.

Because palonosetron competes with other antiemetics, including ondansetron, granisetron, and newer combination products, patent expiry did not create a single-product market. The practical impact of generic entry depended on substitution rules, payer policies, hospital contracts, and the availability of competing 5-HT3 antagonists.

The Fresenius Kabi settlement reduced near-term litigation risk but did not eliminate the broader erosion risk associated with the expiration or weakening of Helsinn's formulation and method-of-use patents.

What is the current legal significance of Helsinn v. Fresenius Kabi?

The case has limited precedential value because it ended without a reported merits decision. Its primary significance is commercial:

• It confirms that Fresenius Kabi challenged the Aloxi patent estate through the ANDA process.
• It demonstrates Helsinn's use of layered formulation and method-of-use patents.
• It shows that settlement, rather than trial, determined the immediate dispute.
• It provides no binding ruling on the validity of the asserted claims.
• It must be read alongside the separate Helsinn v. Teva Supreme Court litigation.

Key Takeaways

• Helsinn sued Fresenius Kabi in the District of Delaware over an ANDA for generic palonosetron injection.
• The asserted patents included U.S. Patent Nos. 7,947,724, 8,598,219, and 8,609,863.
• The case involved Paragraph IV challenges to Aloxi-related patents.
• The action ended through settlement and dismissal without a reported infringement or validity judgment.
• Helsinn's patent estate protected formulations, dosage characteristics, and methods of use rather than palonosetron as a basic compound.
• The Supreme Court's separate Helsinn v. Teva decision increased validity scrutiny for the related patent portfolio but did not decide the Fresenius Kabi case.
• Biosimilar risk was not relevant because palonosetron is a small-molecule drug.
• Generic launch timing depended on confidential settlement terms rather than a public district court judgment.

FAQs About Helsinn Healthcare S.A. v. Fresenius Kabi

What drug was involved in Helsinn v. Fresenius Kabi?

The case involved palonosetron hydrochloride injection, marketed by Helsinn as Aloxi.

Was Fresenius Kabi found to infringe Helsinn's patents?

No reported final merits judgment found Fresenius Kabi liable for infringement. The case was resolved by settlement and dismissed.

Which Helsinn patents were asserted against Fresenius Kabi?

The action involved U.S. Patent Nos. 7,947,724, 8,598,219, and 8,609,863, covering palonosetron formulations and methods of use.

Did the case involve a biosimilar application?

No. Fresenius Kabi's product was a small-molecule generic submitted through the ANDA pathway.

Did Helsinn v. Fresenius Kabi invalidate Aloxi patents?

No. The settlement did not invalidate the asserted patents. Validity issues involving related Helsinn patents were litigated separately, including in the Helsinn v. Teva Supreme Court case.

References

1. Helsinn Healthcare S.A. v. Fresenius Kabi USA, LLC, No. 1:15-cv-00865, Complaint (D. Del. filed July 28, 2015).

2. U.S. Patent No. 7,947,724, Pharmaceutical compositions of palonosetron (issued May 24, 2011).

3. U.S. Patent No. 8,598,219, Methods of treating nausea and vomiting (issued Dec. 3, 2013).

4. Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc., 139 S. Ct. 628 (2019).

5. Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355(j); 35 U.S.C. § 271(e)(2).

6. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.